Dr Roger Liang


School of Biomedical Sciences and Pharmacy (Pharmacy and Experimental Pharmacology)

Career Summary


Dr Liang was trained as a pharmaceutical scientist and has since developed well-equipped research capabilities and leadership in the cross-disciplinary field of advanced drug delivery and nanomedicine. Dr. Liang completed his PhD in Pharmacy from the University of Queensland. His doctoral research theme was to develop nanoparticulate delivery systems for subunit vaccines, which spanned a range of fields including medicinal chemistry, pharmaceutical formulation, and immunology. Toward the end of his PhD, Dr Liang started to engage in research at the interface between polymer science and drug delivery and had gained hands-on experience in a variety of polymerisation and bioconjugation techniques. Upon completion of PhD, Dr Liang took up a postdoctoral position at UQ to investigate the biological interactions and toxicity of precisely engineered nanoparticles. This research had led to some key fundamental discoveries that resulted in several publications in the premium journals including ACS Nano, Nature Nanotechnology, Nanomedicines etc. During this time, Dr Liang was also a research teaching academic at School of Pharmacy and committed to teaching pharmacy undergraduates. After that, Dr Liang joined the Centre for Advanced Macromolecular Design in University of New South Wales, and his research was to develop a platform technology for the efficient delivery of albendazole towards better anti-cancer treatment. In 2011, Dr Liang accepted a lecturer position to establish drug delivery research group at the School of Biomedical Science and Pharmacy in University of Newcastle.

Research Expertise
Dr Liang’s current research centres on advanced drug delivery and nanomedicine, which are at the interface of multidisciplinary fields including chemical & molecular engineering, materials science, chemistry, biotechnology and medicine. His research mainly involves developing novel biomaterials, utilizing self-assembly strategies to formulate biomaterials into desired nano-, micro- and macroscopic structures, and studying applications of these engineered structures for disease treatment and diagnosis.

Teaching Expertise
I mainly teach into pharmaceutics and pharmacy practice within Master of Pharmacy program. In addition, I also deliver guest lectures into Bachelor of Biomedical Science program in the field of drug delivery.


  • PhD, University of Queensland


  • Biomaterials
  • Drug delivery
  • Nanomedicine
  • Pharmaceutics
  • Pharmacy Practice

Professional Experience

UON Appointment

Title Organisation / Department
Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy


For publications that are currently unpublished or in-press, details are shown in italics.

Journal article (21 outputs)

Year Citation Altmetrics Link
2016 Shargh VH, Hondermarck H, Liang M, 'Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion.', Int J Pharm, 515 527-534 (2016) [C1]
DOI 10.1016/j.ijpharm.2016.10.057
Co-authors Hubert Hondermarck
2016 Shargh VH, Hondermarck H, Liang M, 'Antibody-targeted biodegradable nanoparticles for cancer therapy.', Nanomedicine (Lond), 11 63-79 (2016)
DOI 10.2217/nnm.15.186
Citations Scopus - 6Web of Science - 5
Co-authors Hubert Hondermarck
2015 Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL, 'Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model', Journal of Nanobiotechnology, 13 (2015) [C1]
DOI 10.1186/s12951-015-0082-8
2014 Jiang Y, Liang M, Svejkar D, Hart-Smith G, Lu H, Scarano W, Stenzel MH, 'Albumin-micelles via a one-pot technology platform for the delivery of drugs', Chemical Communications, 50 6394-6394 (2014) [C1]
DOI 10.1039/c4cc00616j
2014 Noorani L, Pourgholami MH, Liang M, Morris DL, Stenzel M, 'Albendazole loaded albumin nanoparticles for ovarian cancer therapy', European Journal of Nanomedicine, 6 227-236 (2014) [C1]

© 2014 by De Gruyter 2014.Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, ... [more]

© 2014 by De Gruyter 2014.Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ limits its use as a systemic anticancer agent. To enable systemic administration, we have formulated ABZ into albumin nanoparticles with a size range of 200-300 nm, which were cross-linked with glutaraldehyde to stabilize the nanoparticles and to introduce pH-responsive features. Drug release studies demonstrated that about 20% of ABZ was released at neutral pH within a week in comparison to 70% at slightly acidic condition (pH 5). Cellular uptake studies using ovarian cancer cells indicated that nanoparticles were internalized efficiently within 1 h of incubation. Further, cell proliferation results demonstrated that albumin nanoparticles alone showed no cytotoxicity to both normal and cancer cells. In contrast, the drug-loaded nanoparticles exhibited cellular toxicity and high killing efficacy to cancer cells compared to normal cells. Collectively, our results suggest that these albumin nanoparticles may hold great potentials as ABZ carriers for cancer therapy.

DOI 10.1515/ejnm-2014-0026
Citations Scopus - 1
2013 Deng ZJ, Liang M, Toth I, Monteiro M, Minchin RF, 'Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses', Nanotoxicology, 7 314-322 (2013) [C1]
Citations Scopus - 39
2012 Yhaya F, Sutinah A, Gregory AM, Liang M, Stenzel MH, 'RAFT polymerization of vinyl methacrylate and subsequent conjugation via enzymatic thiol-ene chemistry', Journal of Polymer Science Part A: Polymer Chemistry, 50 4085-4093 (2012) [C1]
Citations Scopus - 7
2012 Lin I-C, Liang M, Liu T-Y, Jia Z, Monteiro M, Toth I, 'Effect of polymer grafting density on silica nanoparticle toxicity', Bioorganic and Medicinal Chemistry, 20 6862-6869 (2012) [C1]
Citations Scopus - 7
2012 Lin I-C, Liang M, Liu T-Y, Monteiro MJ, Toth I, 'Cellular transport pathways of polymer coated gold nanoparticles', Nanomedicine: Nanotechnology Biology and Medicine, 8 8-11 (2012) [C1]
Citations Scopus - 20
2012 Deng ZJ, Liang M, Toth I, Monteiro MJ, Minchin RF, 'Molecular Interaction of Poly(acrylic acid) Gold Nanoparticles with Human Fibrinogen', ACS Nano, 6 8962-8969 (2012) [C1]
Citations Scopus - 61
2011 Lin I-C, Liang M, Liu T-Y, Ziora ZM, Monteiro MJ, Toth I, 'Interaction of Densely Polymer-Coated Gold Nanoparticles with Epithelial Caco-2 Monolayers', Biomacromolecules, 12 1339-1348 (2011) [C1]
Citations Scopus - 28
2011 Deng ZJ, Liang M, Monteiro MJ, Toth I, Minchin RF, 'Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation', Nature Nanotechnology, 6 39-44 (2011) [C1]
Citations Scopus - 339
2011 Yhaya F, Lim J, Kim Y, Liang M, Gregory AM, Stenzel MH, 'Development of Micellar Novel Drug Carrier Utilizing Temperature-Sensitive Block Copolymers Containing Cyclodextrin Moieties', Macromolecules, 44 8433-8445 (2011) [C1]
Citations Scopus - 44
2010 Liang M, Lin I-C, Whittaker MR, Minchin RF, Monteiro MJ, Toth I, 'Cellular uptake of densely packed polymer coatings on gold nanoparticles', ACS Nano, 4 403-413 (2010) [C1]
Citations Scopus - 87
2009 Wu SY, Putral LN, Liang M, Chang H-I, Davies NM, McMillan NAJ, '. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use', Pharmaceutical Research, 26 512-522 (2009) [C1]
Citations Scopus - 28
2008 Sarpietro MG, Micieli D, Pignatello R, Liang M, Toth I, Castelli F, 'Effect of variation in the chain number and length in modulating the interaction of immunogenic lipopeptide with biomembrane models', Thermochimica Acta, 471 14-19 (2008) [C1]
Citations Scopus - 4
2008 Liang M, Davies NM, Toth I, 'Increasing entrapment of peptides within poly(alkyl cyanoacrylate) nanoparticles prepared by interfacial polymerization of water-in-oil microemulsions', International Journal of Pharmaceutics, 362 141-146 (2008) [C1]
Citations Scopus - 13
2008 Koda Y, Liang M, Blanchfield JT, Toth I, 'In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue', International Journal of Pharmaceutics, 356 37-43 (2008) [C1]
Citations Scopus - 19
2008 Liang M, Davies NM, Toth I, 'A novel method for preparing immune stimulating complexes (ISCOMs) by hydration of freeze-dried lipid matrix', European Journal of Pharmaceutics and Biopharmaceutics, 68 840-845 (2008) [C1]
Citations Scopus - 5
2006 Liang M, Davies NM, Blanchfield JT, Toth I, 'Particulate systems as adjuvants and carriers for peptide and protein antigen', Current Drug Delivery, 3 379-388 (2006) [C1]
2005 Liang M, Davies NM, Toth I, 'Encapsulation of lipopeptides within liposomes: Effect of number of lipid chains, chain length and method of liposome preparation', International Journal of Pharmaceutics, 301 247-254 (2005) [C1]
Show 18 more journal articles

Conference (3 outputs)

Year Citation Altmetrics Link
Co-authors Hubert Hondermarck
Co-authors Hubert Hondermarck
2012 Zhao Y, Liang M, Kim Y, Tan X, Zhang L, Stenzel MH, 'Development of core-crosslinked micelles for drug delivery system', Advanced Materials Research (2012) [E1]

Grants and Funding


Number of grants 3
Total funding $162,864

Click on a grant title below to expand the full details for that specific grant.

20171 grants / $136,364

Novel epithelial targets and targeting strategies to prevent asthma exacerbations$136,364

Funding body: Asthma Australia

Funding body Asthma Australia
Project Team Doctor Nathan Bartlett, Conjoint Professor Peter Wark, Doctor Roger Liang, Professor Darryl Knight
Scheme National Research Program
Role Investigator
Funding Start 2017
Funding Finish 2018
GNo G1601217
Type Of Funding Grant - Aust Non Government
Category 3AFG

20151 grants / $25,000

Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Miss Mengna Chi, Doctor Nikki Verrills, Doctor Roger Liang
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1600224
Type Of Funding Grant - Aust Non Government
Category 3AFG

20141 grants / $1,500

4th Annual World Congress of Nanoscience and Technology, Qingdao, P.R.China, 23 - 31 October 2014$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Roger Liang
Scheme Travel Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400985
Type Of Funding Internal
Category INTE

Research Supervision

Number of supervisions


Total current UON EFTSL


Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2016 PhD Novel Targeted Therapy for Airway Remodeling in Asthma PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2013 PhD Multifunctional Nanomedicines Based on Albumin for Targeted Breast Cancer Therapy PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor

Dr Roger Liang


School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Pharmacy and Experimental Pharmacology

Contact Details

Email roger.liang@newcastle.edu.au
Phone (02) 4985 4959
Fax (02) 4921 7903


Room MS117
Building Medical Science Building
Location Callaghan
University Drive
Callaghan, NSW 2308